Výsledky vyhledávání - "Edward Espinal Dominguez"

Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma: INTERACTION phase II study

Autor: Stefano Chong Hun Kim, Jihane Boustani, Dewi Vernerey, Veronique Vendrely, Eric FRANCOIS, Laurent Quero, Francois Ghiringhelli, Christelle De La Fouchardiere, Laetitia Dahan, Olivier Bouché, Benoist Chibaudel, Farid El Hajbi, Chloé Vernet, Magali Rebucci-Peixoto, Edward Espinal-Dominguez, Christophe MARITAZ, Christophe Borg

Publikováno v: Journal of Clinical Oncology. 40:TPS7-TPS7

TPS7 Background: Even though the recurrence rate remains high, chemoradiotherapy (CRT) alone is the standard treatment in locally advanced squamous cell anal carcinoma (SCAC), in the absence of effective neoadjuvant/adjuvant treatment. Modified docet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bdbda8da8b7e5a0b0f3f0db262a54b16
https://doi.org/10.1200/jco.2022.40.4_suppl.tps7

Zobrazit plný text záznamu

The rate of tumor growth during treatment accurately predicts the FDA gold standard of overall survival [OS] in a broad range of malignancies

Autor: Susan E. Bates, Wilfred D. Stein, Montserrat Blanco-Codesido, Martin J. Murphy, Julia Wilkerson, Edward Espinal Dominguez, Antonio Tito Fojo, Elizabeth M. Hecht, Krastan B. Blagoev, John A. Chabot

Publikováno v: Journal of Clinical Oncology. 36:2545-2545

2545Background: Novel clinical trial endpoints that predict overall survival (OS) are needed to streamline anticancer drug development. Methods: We used a novel mathematical approach to estimate si...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9864d98fc1e7cb1dd8a0cab0c7fe6794
https://doi.org/10.1200/jco.2018.36.15_suppl.2545

Zobrazit plný text záznamu

Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC)

Autor: Antonio Tito Fojo, Edward Espinal Dominguez, Mauricio Emmanuel Burotto Pichun, Julia Wilkerson, Krastan B. Blagoev, Montserrat Blanco-Codesido, Pilar Garcia-Alfonso

Publikováno v: Journal of Clinical Oncology. 31:e14592-e14592

e14592 Background: Multiple analyses have concluded anti-EGFR antibodies are detrimental to a majority of patients (pts) whose CRCs harbor mutant KRAS. While panitumumab may benefit some pts with tumors harboring WT KRAS, in the majority the added be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4b058dd204b19e21b49ea203ced8fe96
https://doi.org/10.1200/jco.2013.31.15_suppl.e14592

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání